Avidity Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Avidity Biosciences's estimated annual revenue is currently $21.4M per year.
- Avidity Biosciences's estimated revenue per employee is $122,931
- Avidity Biosciences's total funding is $140.1M.
- Avidity Biosciences has 174 Employees.
- Avidity Biosciences grew their employee count by 38% last year.
Avidity Biosciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Avidity Biosciences?
Avidity Biosciences is pioneering a new class of precision medicines ? antibody-siRNA conjugates (ASC?) ? to deliver nucleic acid therapeutics against genetic drivers of disease. Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates. Importantly, their unique siRNA-based ?payloads? permit selective targeting of disease-associated mRNAs against virtually any target of interest. Our leadership includes seasoned scientists and executives with deep expertise in the fields of antibody conjugation, chemistry, formulations, oligonucleotide therapeutics, drug delivery and cancer biology. Our employees are high energy, creative people who are passionate about solving hard problems and bringing new drugs to patients. We strive to work with partners to discover best-in-class molecules with the goal of long-term, joint value creation. We have also attracted support from top-tier investors including F-Prime Capital, EcoR1 Capital, Brace Pharma and other sophisticated healthcare investors.keywords:N/A
Number of Employees
Employee Growth %
Avidity Biosciences News
Avidity Biosciences (NASDAQ:RNA) Lifted to Hold at Zacks Investment Research. Posted by admin on Apr 21st, 2022.
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody...
(PRNewsfoto/Avidity Biosciences, Inc.) By Avidity Biosciences, Inc., American Academy of Neurology 2022 Annual Meeting...
LA JOLLA, Calif., Jan. 8, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced pipeline updates for 2021 and a research collaborati ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|